Literature DB >> 27122986

Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

Ibrahim Elghissassi1, Saber Boutayeb1, Hanane Inrhaoun1, Hind Mrabti1, Hassan Errihani1.   

Abstract

Entities:  

Year:  2016        PMID： 27122986      PMCID： PMC4835005          DOI： 10.3747/co.23.2849

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  6 in total

1.  Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.

Authors:  Hatice Odabas; Arife Ulas; Kubra Aydin; Mevlude Inanc; Asude Aksoy; Dogan Yazilitas; Mehmet Turkeli; Sinemis Yuksel; Ali Inal; Ahmet S Ekinci; Alper Sevinc; Nebi S Demirci; Mukremin Uysal; Necati Alkis; Faysal Dane; Mehmet Aliustaoglu; Mahmut Gumus
Journal:  Tumour Biol       Date:  2015-07-07

2.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Authors:  Tomoya Kawaguchi; Masahiko Ando; Kazuhiro Asami; Yoshio Okano; Masaaki Fukuda; Hideyuki Nakagawa; Hidenori Ibata; Toshiyuki Kozuki; Takeo Endo; Atsuhisa Tamura; Mitsuhiro Kamimura; Kazuhiro Sakamoto; Michihiro Yoshimi; Yoshifumi Soejima; Yoshio Tomizawa; Shun-ichi Isa; Minoru Takada; Hideo Saka; Akihito Kubo
Journal:  J Clin Oncol       Date:  2014-05-19       Impact factor: 44.544

3.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

4.  Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Authors:  June-Koo Lee; Seokyung Hahn; Dong-Wan Kim; Koung Jin Suh; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Dae Seog Heo
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

5.  An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre.

Authors:  K Ma; V Cohen; G Kasymjanova; D Small; K Novac; J Peterson; A Levit; J Agulnik
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

Review 6.  Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Authors:  Monic Roengvoraphoj; Gregory J Tsongalis; Konstantin H Dragnev; James R Rigas
Journal:  Cancer Treat Rev       Date:  2013-06-12       Impact factor: 12.111
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.